Treatment of attention deficit/hyperactivity disorder with methylphenidate - A post-marketing-surveillance study in community care;Methylphenidatbehandlung von kindern und jugendlichen mit hyperkinetischen störungen: Eine anwendungsbeobachtung bei niedergelassenen ärzten

Nervenheilkunde

Volumn 22, Issue 6, 2003, Pages 311-317

  Banaschewski, T ^a   Uebell, H ^a   Fischer, R ^b   Rothenberger, A ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b MEDICE A Pulter 6mbH/Co KG   (Germany)

Author keywords

ADHD; Community care; Methylphenidate; Post marketing surveillance

Indexed keywords

METHYLPHENIDATE;

APPETITE DISORDER; ATTENTION DEFICIT DISORDER; BLOOD PRESSURE; COMMUNITY CARE; DEPRESSION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAM; ELECTROENCEPHALOGRAM; ENURESIS; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART INFARCTION; HUMAN; MENTAL INSTABILITY; PATIENT COMPLIANCE; POSTMARKETING SURVEILLANCE; QUESTIONNAIRE; REBOUND; REVIEW; SIDE EFFECT; TIC; TREATMENT OUTCOME; TREMOR; WEIGHT REDUCTION;

EID: 0141565215     PISSN: 07221541     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1626305     Document Type: Review

References (39)

1. AACAP. Practice Parameter for the Use of Stimulant Medications in the Treatment of Children, Adolescents and Adults. J Am Acad Child Adolesc Psychiatry 2002; 41(2nd Suppl): 46S-9S.
2. Applegate B, Lahey BB, Hart EL, Biederman J, Hynd GW, Barkley RA, et al. Validity of the age-of-onset criterion for ADHD: a report from the DSM-IV field trials. J Am Acad Child Adolesc Psychiatry 1997; 36(9): 1211-21.
3. Banaschewski T, Rothenberger A. Medikamentöse Behandlung der Aufmerksamkeitsdefizit-Hyperaktivitätsstörung im Kindesalter unter Berücksichtigung komorbider Aspekte. Sprache-Stimme-Gehör 2000; 24: 99-105.
4. Banaschewski T, Rothenberger A, Besmens F, Zieger H. Evaluation of sensorimotor training in ADHD children. Perceptual and Motor Skills 2001; 92: 137-49.
5. Barkley RA, Biederman J. Toward a broader definition of the age-of-onset criterion for attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1997; 36(9): 1204-10.
6. Barkley RA, Murphy KR. Attention-deficit hyperactivity disorder: A clinical workbook. 2nd ed. New York: The Guilford Press 1998.
7. Barkley RA. Consensus Statement on ADHD. January 2002. Eur Child Adolesc Psychiatry 2002; 11: 96-8.
8. Baving L, Schmidt MH. [Evaluated treatment approaches in child and adolescent psychiatry I]. Z Kinder Jugendpsychiatr Psychother 2001; 29(3): 189-205.
9. Biederman J, Faraone S, Milberger S, Guite J, Mick E, Chen L, et al. A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders. Arch Gen Psychiatry 1996; 53(5): 437-46.
10. Biederman J, Wilens T, Mick E, Spencer T, Faraone SV. Pharmacotherapy of attentiondeficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics 1999; 104(2): e20.
11. Conners CK. The Conners Rating Scales: Instruments for the assessment of childhood psychopathology. New York: North Tonawanda 1995.
12. DGKJPP. Leitlinien zur Diagnostik und Therapie von psychischen Störungen. Köln: Deutscher Arzteverlag 2000.
13. Döpfner M, Banaschewski T, Schmidt J, Uebel H, Schmeck K, Gerber WD, et al. Langzeitwirksames Methylphenidat (Medikinet Retard®) bei Kindern mit Aufmerksamkeitsdefizit-/Hyperaktivitätsstörungen - erfolgreiche Symptomreduktion und gute Verträglichkeit in einer multizentrischen Studie. Nervenheilkunde 2003; 22: 85-92.
14. Fachverbände-für-KJPP. Stellungnahme der Fachverbände für Kinder- und Jugendpsychiatrie und Psychotherapie in Deutschland zur Behandlung hyperkinetischer Störungen im Kindesalter mit Methylphenidat. Forum der Kinder- und Jugendpsychiatrie und Psychotherapie 1999; 9: 21-3.
15. Faraone SV, Biederman J. Neurobiology of attention-deficit hyperactivity disorder. Biol Psychiatry 1998; 44(10): 951-8.
16. Gillberg C, Melander H, von Knorring AL, Janols LO, Thernlund G, Hagglof B, et al. Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms. A randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 1997; 54(9): 857-64.
17. Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, et al. Summary of the practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2001; 40(11): 1352-5.
18. Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002; 41(2 Suppl): 26S-49S.
19. Huss M, Schmidt-Schulz E, Englert G, Lehmkuhl G, Poustka F, Lehmkuhl U. Abhängigkeitsentwicklung bei Kindern mit Hyperkinetischem Syndrom am Beispiel der Nikotinabhängigkeit. Abstractband des XXVI. Kongresses der Deutschen Gesellschaft für Kinder- und Jugendpsychiatrie 2000: 180.
20. Jensen PS, Kettle L, Roper MT, Sloan MT, Dulcan MK, Hoven C, et al. Are stimulants over-prescribed? Treatment of ADHD in four U.S. communities. J Am Acad Child Adolesc Psychiatry 1999; 38(7): 797-804.
21. Jensen PS. Commentary: the NIH ADHD Consensus Statement: win, lose, or draw? J Am Acad Child Adolesc Psychiatry 2000; 39(2): 194-7.
22. Jensen PS. Are stimulants overprescribed? Letter to the editor. Journal of the American Academy of Child and Adolescent Psychiatry 2000; 3: 270-1.
23. Lehmkuhl G, Dopfner M, Pluck J, Berner W, Fegert JM, Huss M, et al. [Incidence of psychiatric symptoms and somatic complaints in 4- to 10-year-old children in Germany as judged by parents - a comparison of norm-oriented and criteria-oriented models]. Z Kinder Jugendpsychiatr Psychother 1998; 26(2): 83-96.
24. Lojewski I, Wismann B, Höger C, Rothenberger A, Havemann-Reinecke U. Sind mit Methylphenidat therapierte Menschen einem erhöhten Missbrauchs- und Abhängigkeitsrisiko ausgesetzt? In: Richter G, Rommelspacher H, Spies C (eds). Alkohol, Nikotin, Kokain ... und kein Ende? Lengerich: Pabst 2002: 457-63.
25. MTA-Cooperative-Study. Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of children with Attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999; 56(12): 1088-96.
26. MTA-Cooperative-Study. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 1999; 56(12): 1073-86.
27. Overmeyer S, Taylor E. Annotation: Principles of treatment for hyperkinetic disorder: practice approaches for the U.K. J Child Psychol Psychiatry 1999; 40(8): 1147-57.
28. Pelham WE Jr., Wheeler T, Chronis A. Empirically supported psychosocial treatments for attention deficit hyperactivity disorder. J Clin Child Psychol 1998; 27(2): 190-205.
29. Rothenberger A, Banaschewski T. Kontrolluntersuchungen bei Methylphenidattherapie. Pädiatrische Praxis 2002; 61: 157-60.
30. Rothenberger A, Resch F. Aufmerksamkeitsdefizit-Hyperaktivitatsstö rung (ADHS) und Stimulanzien - nur evidenzbasierte Sachlichkeit hilft. Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie 2002; 30: 159-61.
31. Rothenberger A, Banaschewski T. Towards a better drug treatment for patients in Child and Adolescent Psychiatry - the European approach. European Child and Adolescent Psychiatry 2002; 11: 243-6.
32. Schleimer K, Gustafsson P. Die Behandlung mit Stimulantien bei ADHD in Schweden (Deutsche Zusammenfassung der offiziellen staatlichen Regelungen). Schweden: Klinik für Kinder- und Jugendpsychiatrie Malmö 2002.
33. Schubert I, Lehmkuhl G, Sprengler A, Döpfner M, von Ferber L. Methylphenidat bei hyperkinetischen Störungen. Verordnungen in den 90er Jahren. Deutsches Ärzteblatt 2001; 98: A-541.
34. Spencer T, Biederman J, Wilens T. Pharmacotherapy of attention deficit hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 2000; 9(1): 77-97.
35. Swanson JM, McBumett K, Christian DL, Wigal T. Stimulant Medications and the Treatment of Children with ADHD. In: Ollendieck TH, Prinz RJ (eds). Advances in Clinical Child Psychology 1995: 265-322.
36. Taylor E, Sergeant J, Doepfner M, Gunning B, Overmeyer S, Mobius HJ, et al. Clinical guidelines for hyperkinetic disorder. European Society for Child and Adolescent Psychiatry. Eur Child Adolesc Psychiatry 1998; 7(4): 184-200.
37. Vitiello B. Long-term effects of stimulant medications on the brain: possible relevance to the treatment of attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2001; 11(1): 25-34.
38. Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, Ding YS, et al. Blockade of striatal dopamine transporters by intravenous methylphenidate is not sufficient to induce self-reports of «high». J Pharmacol Exp Ther 1999; 288(1): 14-20.
39. Volkow ND, Wang G, Fowler JS, Logan J, Gerasimov M, Maynard L, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 2001; 21(2): RC121.